

1 **Clinical Practice Guideline: Tobacco Cessation Counseling**

2
3 **Date of Implementation: April 19, 2012**

4
5 **Product: Specialty**

6
7
8 **GUIDELINES**

9 American Specialty Health – Specialty (ASH) clinical committees determined that in the
10 context of best practices and for the population of all patients, the evaluation of tobacco
11 use is necessary. In this same context, a brief intervention for the population of tobacco
12 users is recommended. An example of a brief intervention would be what is recommended
13 by the United States Preventive Services Task Force (USPSTF) for tobacco users. Lastly,
14 ASH clinical committees concluded in the same context of best practices for the population
15 of tobacco users, a direct intervention or referral, depending upon the expertise and scope
16 of the practitioner, for appropriate tobacco cessation intervention is necessary.

17
18 **PROCESS AND DEFINITIONS**

19 When developing, reviewing, and approving clinical policy, ASH peer-review committees
20 considered:

- 21 • Patient Population – Persons presenting in practitioners’ offices whose primary
22 complaint is likely (although not necessarily) musculoskeletal pain and who have
23 been properly evaluated and diagnosed. This patient population may be further
24 defined by age, gender, clinical status.
- 25 • Opportunity for evaluation – Given the defined population and within the context
26 of the practitioner’s scope of practice, the degree to which accurate and actionable
27 information can be practically obtained regarding the modifiable risk factor.
- 28 • Opportunity for intervention – Given the defined population and (i) within the
29 context of the practitioner’s scope of practice and (ii) given an appropriate
30 evaluation of the modifiable risk factor, the degree to which the modifiable risk
31 factor can be effectively improved, either directly by the practitioner or by referral
32 to an appropriate resource.
- 33 • Potential Impact – Assuming appropriate evaluation and intervention, the degree to
34 which improvement in the modifiable risk factor can improve health. This potential
35 impact will be considered in three different clinical contexts:
- 36 ○ Its impact on a presenting complaint of musculoskeletal pain.
 - 37 ○ Its impact on a specific chronic condition.
 - 38 ○ Its impact on general health and prevention. This includes prevention of
39 cardiovascular disease, cancer and other conditions, improvement or
40 maintenance of physical functional capacity and quality of life.

- Based upon the degree of potential impact, recommendations for best practice will be categorized as one of five options:
 - Necessary (should be done);
 - Recommended (should be considered by the practitioner);
 - Discretionary (up to the practitioner to determine);
 - Unnecessary (not recommended); or
 - Contraindicated (should not be done).

INTRODUCTION

Tobacco use is the leading preventable cause of death in the U.S. This is more than the combined total from AIDS, alcohol, cocaine, heroin, homicide, suicide, motor vehicle crashes, and fires. The association between tobacco use and premature death is one of the best documented in the epidemiological literature, beginning with Doll’s study of over 40,000 male physicians in 1951; this study then continued, following participants for 50 years. These studies showed that cigarette smokers had twice the death rate ratio as nonsmokers (42% to 24%) for premature death (at ages 35-69). Cigarette smoking was found to be highly correlated with all causes of death, as was number of cigarettes smoked, which demonstrates a strong dose-response effect.

Smoking causes cancer, heart disease, stroke, lung diseases such as COPD, and diabetes. Some studies suggest that tobacco use may be a risk factor for low back pain and may contribute to poorer outcomes in people with musculoskeletal back pain, including outcomes of rehabilitation care.

Electronic cigarettes are an emerging issue in tobacco use and cessation. According to the Centers for Disease Control, in 2022, more than 2.55 million U.S. middle and high school students had used e-cigarettes in the past 30 days. This includes 14.1% of high school students and 3.3% middle school students (Centers for Disease Control and Prevention, 2022). The Food and Drug Administration reported that e-cigarette use, from 2017 to 2018, increased 78 percent among high school students and 48 percent among middle school students. Additionally, 4.5% of adults aged 18 or older are e-cigarette users, with highest use among those between 18-24 years of age. Adults who are between the ages of 18-44 are more likely to smoke both cigarettes and e-cigarettes in comparison with adults 45 years of age or older (Kramarow & Elgaddal, 2023).

E-cigarettes are not currently approved by the FDA as a quit smoking aid. The U.S. Preventive Services Task Force, has concluded that evidence is insufficient to “assess the balance of benefits and harms of e-cigarettes for tobacco cessation in adults, including pregnant persons.” The USPSTF (2021) recommends that clinicians direct patients who use tobacco to other tobacco cessation interventions with proven effectiveness and established safety. Based on evolving evidence, ASH does not currently support e-cigarettes as a viable method of tobacco cessation or nicotine replacement.

1 An office visit with a health care practitioner can provide an opportunity to talk with
 2 patients about their tobacco use. Given the health effects associated with chronic tobacco
 3 use, the office visit provides a "teachable moment" during which a qualified healthcare
 4 professional can relate current health problems to tobacco use, provide brief counseling, or
 5 set an appropriate referral for patients who use tobacco products.

6 7 **SCREENING RECOMMENDATIONS**

8 The 2008 U.S. Department of Health and Human Services (USDHHS) clinical practice
 9 guideline on treating tobacco use and dependence recommends that all patients should be
 10 asked if they use tobacco, and this status should be documented regularly in their records
 11 (Fiore et al., 2008).

12
 13 Inclusion of tobacco use status has been recommended in patient intake forms and clinic
 14 screening systems as a fifth vital sign.

15
 16 The strength of evidence for this recommendation was designated as Level A, meaning that
 17 “multiple well-designed randomized clinical trials, directly relevant to the
 18 recommendation, yielded a consistent pattern of findings.” In a meta-analysis of nine
 19 studies, it was found that including patient report of tobacco use status in patient records
 20 through the use of screening systems significantly increased the rate of clinician
 21 intervention. However, a meta-analysis showed that use of a clinic system to identify and
 22 track patients’ tobacco use status, alone, did not significantly increase rates of cessation.

23
 24 In addition, the USPSTF(2021) provided the following recommendations for adults:

25 *Grade A Recommendation:* Clinicians should ask all adults about tobacco use, advise
 26 them to stop using tobacco and provide behavioral interventions and US Food and Drug
 27 Administration (FDA) approved pharmacotherapy for cessation to nonpregnant adults
 28 who use tobacco.

29 *Grade A Recommendation:* Clinicians should ask all pregnant persons about tobacco
 30 use, advise them to stop using tobacco and provide behavioral interventions for
 31 cessation to pregnant persons who use tobacco.

32 33 **Documentation Requirements to Substantiate Medical Necessity**

CPT® Code	CPT® Code Description
99406	Smoking and tobacco use cessation counseling visit; intermediate, greater than three (3) minutes up to 10 minutes
99407	Smoking and tobacco use cessation counseling visit; intensive, greater than 10 minutes

1 The 5A's comprise a framework frequently used in clinical practice to guide behavioral
 2 interventions. Within the following 5 A's are examples of how each step can be applied to
 3 tobacco cessation.

4
 5 **1) Ask:**

- 6 • Ask every patient about tobacco use at each visit.
- 7 • Record the response in the patient's chart.

8
 9 **2) Advise:**

- 10 • Provide the patient with a clear, non-judgmental statement about how important it
 11 is to stop smoking.
- 12 • Discuss the increased risk of tobacco use to the patient's health.
- 13 • Discuss benefits of quitting for health, family, and economics (e.g., cost savings).

14
 15 **3) Assess:**

- 16 • Ask the patient about their willingness to quit.
- 17 • Provide interventions to a patient not yet willing to quit. Explore why they are not
 18 motivated to quit at this time. What are the advantages and disadvantages of
 19 smoking? Identify patient's core values and how they are related to tobacco use.
- 20 • If they are willing to quit, offer brief intervention, referral sources, schedule follow
 21 up plan.
- 22 • Assess for any medical and/or psychological condition(s) which may contraindicate
 23 or complicate tobacco cessation (e.g., COPD, schizophrenia). Consultation with the
 24 primary care physician in such circumstances should be obtained prior to cessation
 25 of tobacco use.

26
 27 **4) Assist:**

- 28 • Help the patient make a quit plan. Set a date, ideally within two weeks.
- 29 • Help the patient change their environment (e.g., cleaning ash trays out of the home).
- 30 • Assist patient with establishing a social support system for help with quitting.
- 31 • Identify and plan for dealing with tobacco triggers or other challenges before or
 32 after quitting tobacco (e.g., co-workers who smoke, stress).
- 33 • Discuss relapse prevention; Develop coping skills to maintain a desire to quit.
- 34 • Ask about the patient's interest in medications and refer if medications are desired.
- 35 • Provide supplemental self-help materials and referrals information such as quit
 36 lines.
- 37 • Assess for environmental barriers (e.g., others smoking at home).
- 38 • Discuss previous quit attempts (successes and/or barriers).
- 39 • Given alcohol's relation to relapse, consider limiting use while quitting.
- 40 • Discuss nicotine withdrawal symptoms.

- 1 • Discuss steps taken prior to quitting, such as removing all tobacco products from
- 2 patient’s environment, and avoiding smoking in places where patient spends a
- 3 majority of their time.
- 4 • Discuss making home smoke-free.
- 5 • Provide support to address family and friends who use tobacco.
- 6 • Provide encouragement and support to quit.

8 5) **Arrange:**

- 9 • Follow up within the first week after quit date and again within the first month.
- 10 • Follow-up can be by phone, texting, in person or by e-mail.
- 11 • Congratulate successes.
- 12 • Provide out of office visit clinician support to maintain quitting (e.g., email, phone,
- 13 texting, walk-in).
- 14 • Encourage and support a prolonged quitting.
- 15 • Relapse prevention/intervention to support long term tobacco cessation.
- 16 • Reinforce the positive health benefits immediately following quitting and for
- 17 prolonged cessation.
- 18 • Records should indicate that patients participating in a tobacco cessation program
- 19 are asked about their tobacco use at every visit (prior, during, and after quitting).

20
21 According to the USPSTF, there is a dose-response relationship between quit rates and the
22 intensity of counseling (that is, more or longer sessions improve quit rates). Quit rates
23 appear to plateau after 90 minutes of total counseling contact time. Combination therapy
24 with counseling and medications is more effective at increasing cessation rates than either
25 component alone.

26 **EFFECTIVE INTERVENTIONS**

27 **Counseling:** Community-based tobacco-control programs have been effective, judging by
28 the decline in adult smoking prevalence in the U.S. from 20.9% in 2005 to 11.5% in 2021
29 (Centers for Disease Control and Prevention, 2023, May 4). At the individual level, it has
30 been documented that personalized advice from their doctor influences patients to quit,
31 when compared to patients not advised to quit. Brief counseling of 3 minutes or less by a
32 physician has been shown to be effective in achieving prolonged abstinence, compared to
33 no intervention. Higher-intensity counseling sessions >10 minutes have achieved
34 abstinence rates of 22.1%, nearly twice those of brief counseling of <3 minutes, 13.4%.
35 Use of state quit lines for telephone counseling has been shown to be effective compared
36 to no counseling or self-help only.

37 **Evidence-Based Behavior Modification Techniques**

38
39 A recommendation published by the Department of Health and Human Services (Fiore et
40 al., 2008) reported that 2 types of counseling and behavioral therapies result in higher
41

1 abstinence rates: (1) providing smokers with practical counseling (problem solving
2 skills/skills training), and (2) providing support and encouragement as part of treatment.
3 The panel recommended that these types of counseling elements should be included in
4 smoking cessation interventions. Examples of these include:

- 5 • **Problem solving/ skills training:** Recognize danger situations – Identify events,
6 internal states, or activities that increase the risk of smoking or relapse.
- 7 • **Develop coping skills:** Identify and practice coping or problem solving skills.
8 Typically, these skills are intended to cope with danger situations.
- 9 • **Provide basic information:** Provide basic information about smoking and
10 successful quitting.

11
12 According to a meta-analysis by Hartmann-Boyce et al. (2021), smoking cessation rates
13 can be increased at 6 months or longer through behavioral support without evidence that
14 suggests that there is increased harm. This is true whether or not psychopharmacotherapy
15 is also provided, although this effect is slightly more pronounced when the latter is absent.
16 In fact, evidence of benefits is strongest when counseling of any kind is employed and
17 guaranteed financial incentives. There might also be benefit from interventions that are
18 more individually tailored; delivered by text message, email or audio recording; delivered
19 by a lay health advisor; and content with motivational components, as well as a focus on
20 how to quit.

21
22 Counseling can be effective when used alone, however the combination of counseling and
23 medication is more effective than either strategy used on its own (Stead et al., 2012). The
24 use of medications is effective in combination with counseling, except for situations in
25 which it may be contraindicated, or with populations in which medication use has not been
26 found to be effective.


27
28 **Medications:** In addition to counseling, all smokers making a quit attempt may be offered
29 medications, or referrals for medication evaluations as appropriate.

30
31 Though evidence and guidelines suggest medication, practitioners must consult within
32 their scope of licensure. This guideline does not suggest communication about medication
33 if such activity is outside the practitioner’s scope of practice.

34
35 Over-the-counter products include nicotine gum, patches, and lozenges. It is important to
36 thoroughly review the directions prior to use. Prescription nicotine replacement products
37 include nasal and oral inhalers. Oral prescription medications for tobacco cessation that do
38 not contain nicotine include bupropion and varenicline. Electronic cigarettes (e-cigarettes
39 or electronic nicotine delivery systems) are a group of products that generally provide
40 aerosolized nicotine without the use of tobacco. They are readily available to the public
41 and are touted as an aid to tobacco cessation or as a replacement for cigarettes where
42 smoking is prohibited (Grana, 2014). The short- and long-term efficacy and comparative

1 efficacy with approved tobacco cessation products is not yet fully known. A systematic
2 review showed good results with smoking abstinence at one month, but abstinence at 3 and
3 6 months was the same as placebo (McRobbie et al., 2014). The toxicity of e-cigarettes is
4 not yet clear and further research is needed to evaluate their safety for the direct user and
5 those with second-hand exposure (Hartmann-Boyce et al., 2021). When used as a
6 therapeutic intervention, the use of e-cigarettes may have a negative effect on nicotine
7 abstinence in comparison to nicotine replacement therapies. This is, most smokers who
8 quit smoking cigarettes with the help of e-cigarettes continued using e-cigarettes until the
9 end of random controlled trails (Hanewinkel et al., 2022).

10
11 The practitioner should carry out an assessment to determine the most appropriate course
12 of tobacco cessation treatment for the patient. Figure 1 provides a guideline (adapted from
13 Hughes, 2013) which the practitioner can utilize for the assessment and management of
14 tobacco cessation treatment. If the counseling and/or medication interventions are outside
15 of the expertise and scope of practice of the practitioner, then it is helpful to educate the
16 patient that counseling and medication can be effective and refer the patient to an
17 appropriate health care professional for further assistance.



1
2 Figure 1: Tobacco Cessation Intervention Assessment Algorithm (adapted from Hughes,
3 2013)

1 Nicotine withdrawal symptoms include irritability, cravings, depression, anxiety, cognitive
2 and attention deficits, sleep disturbances, and increased appetite. These symptoms may
3 begin within a few hours after the last cigarette, quickly driving people back to tobacco
4 use. Symptoms peak within the first few days of smoking cessation and may subside within
5 a few weeks. For some people, however, symptoms may persist for months. The former
6 tobacco user should receive recognition of any success made during a quit attempt, and
7 also receive strong encouragement to remain abstinent. Relapse is most likely to occur soon
8 after quitting, but the risk for relapse can continue for months, or even years. All very
9 recent quitters should be given assistance; therefore, it is important to regularly ask those
10 who have quit if they are facing any challenges, such as temptations to smoke, close calls
11 for slips and relapses, or serious thoughts about starting again. Former tobacco users who
12 report such challenges should be given additional tobacco cessation assistance.

13 14 **PRACTITIONER SCOPE AND TRAINING**

15 Practitioners should practice only in the areas in which they are competent based on their
16 education training and experience. Levels of education, experience, and proficiency may
17 vary among individual practitioners. It is ethically and legally incumbent on a practitioner
18 to determine where they have the knowledge and skills necessary to perform such services
19 and whether the services are within their scope of practice.

20
21 It is best practice for the practitioner to appropriately render services to a patient only if
22 they are trained to competency, equally skilled, and adequately competent to deliver a
23 service compared to others trained to perform the same procedure. If the service would be
24 most competently delivered by another health care practitioner who has more skill and
25 training, it would be best practice to refer the patient to the more expert practitioner.

26
27 Best practice can be defined as a clinical, scientific, or professional technique, method, or
28 process that is typically evidence-based and consensus driven and is recognized by a
29 majority of professionals in a particular field as more effective at delivering a particular
30 outcome than any other practice (Joint Commission International Accreditation Standards
31 for Hospitals, 2020).

32
33 Depending on the practitioner's scope of practice, training, and experience, a patient's
34 condition and/or symptoms during examination or the course of treatment may indicate the
35 need for referral to another practitioner or even emergency care. In such cases it is essential
36 for the practitioner to refer the patient for appropriate co-management (e.g., to their primary
37 care physician) or if immediate emergency care is warranted, to contact 911 as appropriate.
38 See the *Managing Medical Emergencies (CPG 159 – S)* clinical practice guideline for
39 information.

1 PRACTITIONER RESOURCES

2 One way to assist patients with tobacco cessation is by using a tear sheet. The tear sheet
3 can allow clinicians to individualize an intervention and can be given to patients as a
4 takeaway.

- 5 • Tear Sheet for Use with Patients – English
6 ([http://www.ahrq.gov/sites/default/files/wysiwyg/professionals/clinicians-
9 providers/guidelines-
10 recommendations/tobacco/clinicians/tearsheets/tearsheet.pdf](http://www.ahrq.gov/sites/default/files/wysiwyg/professionals/clinicians-
7 providers/guidelines-
8 recommendations/tobacco/clinicians/tearsheets/tearsheet.pdf))
- 11 • Quick Reference Guide for Clinicians
12 ([https://www.ahrq.gov/sites/default/files/wysiwyg/professionals/clinicians-
15 providers/guidelines-
16 recommendations/tobacco/clinicians/references/quickref/tobaqrg.pdf](https://www.ahrq.gov/sites/default/files/wysiwyg/professionals/clinicians-
13 providers/guidelines-
14 recommendations/tobacco/clinicians/references/quickref/tobaqrg.pdf))
- 17 • Material Links for Clinical Websites and Blogs (<http://www.smokefree.gov/>)

15 Spanish Language

- 16 • Tear Sheet for Use with Patients - Spanish
17 ([http://www.ahrq.gov/professionals/clinicians-providers/guidelines-
19 recommendations/tobacco/clinicians/tearsheets/tearsheetsp.html](http://www.ahrq.gov/professionals/clinicians-providers/guidelines-
18 recommendations/tobacco/clinicians/tearsheets/tearsheetsp.html))
- 20 • Material links for Clinical Websites and Blogs – Spanish
21 (<https://espanol.smokefree.gov/>)

22 MEMBER RESOURCES

23 Educating patients about tobacco cessation options and available resources can assist the
24 patient. Publicly available resources can be found at:

- 25 • Tobacco Cessation – What You Need to Know About Smoking
26 ([http://www.cdc.gov/tobacco/data_statistics/sgr/50th-anniversary/pdfs/what-you-
28 need-to-know.pdf](http://www.cdc.gov/tobacco/data_statistics/sgr/50th-anniversary/pdfs/what-you-
27 need-to-know.pdf))
- 29 • Tools to Help You Quit (<https://www.smokefree.gov/>)

30 Federal resources are available to patients to assist in quitting tobacco products:

- 31 • Visit <https://smokefree.gov/>
- 32 • Visit the CDC’s website on how to quit smoking (with links to Spanish content as
33 well): <https://www.cdc.gov/tobacco/campaign/tips/quit-smoking/index.html>
- 34 • Talk to a Smoking Cessation Counselor
 - 35 ○ Call 1-800-QUITNOW (1-800-784-8669), a national portal to a network
36 of state quitlines
 - 37 ○ American Lung Association: Lung Helpline and Tobacco Quitline:
 - 38 ▪ 1-800-LUNG-USA (1-800-586-4872) & for the hearing impaired
39 TTY 1-800-501-1068
- 40 • Get Instant Messaging Live Help
41 (https://livehelp.cancer.gov/app/chat/chat_launch)

- 1 • Approved Smoking Cessation Products
- 2 (<http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm198176.htm>)

4 **References**

- 5 Ahluwalia, J.S., Gibson, C. A., Kenney, R. E., Wallace, D. D., & Resnicow, K. (1999).
6 Smoking status as a vital sign. *Journal of General Internal Medicine*, 14(7), 402-408
- 7
- 8 American Medical Association. (current year). *Current Procedural Terminology (CPT)*
9 *Current year (rev. ed.)*. Chicago: AMA
- 10
- 11 MedlinePlus. (n.d.). *Smoking cessation medications* Retrieved on March 4, 2024 from
12 <https://medlineplus.gov/ency/article/007439.htm>
- 13 Centers for Disease Control and Prevention. About Electronic Cigarettes (E-Cigarettes).
14 Retrieved on January 22, 2024 from
15 https://www.cdc.gov/tobacco/basic_information/e-cigarettes/about-e-cigarettes.html
- 16
- 17 Centers for Disease Control and Prevention. Current cigarette smoking among adults in the
18 United States. Retrieved January 22, 2024, from
19 https://www.cdc.gov/tobacco/data_statistics/fact_sheets/adult_data/cig_smoking/index.htm
20
- 21
- 22 Centers for Disease Control and Prevention. (n.d.). *Current cigarette smoking among*
23 *adults in the United States*. Centers for Disease Control and Prevention. Retrieved
24 January 3, 2024 from
25 https://www.cdc.gov/tobacco/data_statistics/fact_sheets/adult_data/cig_smoking/index.htm
26
- 27
- 28 Centers for Disease Control and Prevention. More than 2.5 million youth reported e-
29 cigarette use in 2022. Retrieved January 22, 2024, from
30 <https://www.cdc.gov/media/releases/2022/p1007-e-cigarette-use.html>
- 31
- 32 Cherkin DC, Deyo RA, Sherman KJ, et al. Characteristics of visits to licensed
33 acupuncturists, chiropractors, massage therapists, and naturopathic physicians. *J Am*
34 *Board Fam Pract*. Nov-Dec 2002;15(6):463-472
- 35
- 36 Doll, R., & Hill, A. B. (2004). The mortality of doctors in relation to their smoking habits:
37 A preliminary report. 1954. *BMJ*, 328(7455), 1529-1533; discussion 1533
- 38
- 39 Doll, R., Peto, R., Boreham, J., & Sutherland, I. (2004). Mortality in relation to smoking:
40 50 years' observations on male British doctors. *BMJ*, 328(7455), 1519

- 1 Farelley M, Pechacek, TF, Thomas, KY, Nelson, D. The impact of tobacco control
2 programs on adult smoking. *Am J Public Health*. Feb 2008 2008;98(2):304-309
3
- 4 Fiore MC, Jaén CR, Baker TB, et al. Treating Tobacco Use and Dependence: 2008
5 Update. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and
6 Human Services. Public Health Service. May 2008 Retrieved on January 22, 2024 from
7 <https://www.ncbi.nlm.nih.gov/books/NBK63952/>
8
- 9 Goldberg MS, Scott SC, Mayo NE. A review of the association between cigarette smoking
10 and the development of nonspecific back pain and related outcomes. *Spine (Phila Pa*
11 *1976)*. Apr 15 2000;25(8):995-1014
12
- 13 Grana, R., Benowitz, N., & Glantz, S. A. (2014). E-cigarettes: a scientific review.
14 *Circulation*, 129(19), 1972–1986.
15 <https://doi.org/10.1161/CIRCULATIONAHA.114.007667>
16
- 17 Hanewinkel, R., Niederberger, K., Pedersen, A., Unger, J. B., & Galimov, A. (2022). E-
18 cigarettes and nicotine abstinence: A meta-analysis of randomised controlled trials.
19 *European Respiratory Review*, 31(163), 210215.
20 <https://doi.org/10.1183/16000617.0215-2021>
21
- 22 Hartmann-Boyce, J., McRobbie, H., Lindson, N., Bullen, C., Begh, R., Theodoulou, A.,
23 Notley, C., Rigotti, N. A., Turner, T., Butler, A. R., Fanshawe, T. R., & Hajek, P.
24 (2022). Electronic cigarettes for smoking cessation. *The Cochrane database of*
25 *systematic reviews*, 4(4), CD010216.
26 <https://doi.org/10.1002/14651858.CD010216.pub5>
27
- 28 Hartmann-Boyce J, Livingstone-Banks J, Ordóñez-Mena JM, Fanshawe TR, Lindson N,
29 Freeman SC, Sutton AJ, Theodoulou A, & Aveyard P. (2021). Behavioural
30 interventions for smoking cessation: an overview and network meta-analysis.
31 *Cochrane Database of Systematic Reviews*, 1, CD013229
32
- 33 Hays JT, Ebbert JO, Sood A. Treating tobacco dependence in light of the 2008 US
34 Department of Health and Human Services clinical practice guideline. *Mayo Clin Proc*.
35 Aug 2009;84(8):730-735; quiz 735-736
36
- 37 Hill FJ. Complementary and alternative medicine: the next generation of health promotion?
38 *Health Promot Int*. Sep 2003;18(3):265-272
39
- 40 Hughes, J. (2013). An updated algorithm for choosing among smoking cessation
41 treatments. *Journal of Substance Abuse Treatment*, 45(2), 215

- 1 Joint Commission International. (2020). Joint Commission International Accreditation
2 Standards for Hospitals (7th Edition): Joint Commission Resources.
3
- 4 Kramarow EA, & Elgaddal N. (2023). Current electronic cigarette use among adults aged
5 18 and over: United States, 2021. Retrieved March 4, 2024 from
6 <https://www.cdc.gov/nchs/data/databriefs/db475.pdf>
7
- 8 Kreuter, M.W., Chheda, S. G., & Bull, F. C. (2000). How does physician advice influence
9 patient behavior? Evidence for a priming effect. *Archives of Family Medicine*, 9(5),
10 426-433
11
- 12 McGearry DD, Mayer TG, Gatchel RJ, Anagnostis C. Smoking status and
13 psychosocioeconomic outcomes of functional restoration in patients with chronic
14 spinal disability. *Spine J.* Mar-Apr 2004;4(2):170-175
15
- 16 McRobbie, H., Bullen, C., Hartmann-Boyce, J., & Hajek, P. (2014). Electronic cigarettes
17 for smoking cessation and reduction. *The Cochrane database of systematic reviews*,
18 (12), CD010216. <https://doi.org/10.1002/14651858.CD010216.pub2>
19
- 20 Mokdad, A. H., Marks, J. S., Stroup, D. F., & Gerberding, J. L. (2004). Actual causes of
21 death in the United States, 2000. *JAMA*, 291(10), 1238-1245
22
- 23 National Institute on Drug Abuse. (2022). Tobacco, Nicotine, and E-Cigarettes Research
24 Report. Retrieved on January 22, 2024 from
25 [https://www.drugabuse.gov/publications/research-reports/tobacco-nicotine-e-](https://www.drugabuse.gov/publications/research-reports/tobacco-nicotine-e-cigarettes/introduction)
26 [cigarettes/introduction](https://www.drugabuse.gov/publications/research-reports/tobacco-nicotine-e-cigarettes/introduction)
27
- 28 Okuyemi, K. S., Nollen, N. L., & Ahluwalia, J. S. (2006). Interventions to facilitate
29 smoking cessation. *American family physician*, 74(2), 262–271
30
- 31 Patel, M. S., & Steinberg, M. B. (2016). In the Clinic. Smoking Cessation. *Annals of*
32 *internal medicine*, 164(5), ITC33–ITC48. <https://doi.org/10.7326/AITC201603010>
33
- 34 Pincus, T., Santos, R., Breen, A., Burton, A. K., Underwood, M., & Multinational
35 Musculoskeletal Inception Cohort Study Collaboration (2008). A review and proposal
36 for a core set of factors for prospective cohorts in low back pain: a consensus
37 statement. *Arthritis and rheumatism*, 59(1), 14–24. <https://doi.org/10.1002/art.23251>
38
- 39 Rehtine GR, 2nd, Frawley W, Castellvi A, Gowski A, Chrin AM. Effect of the spine
40 practitioner on patient smoking status. *Spine (Phila Pa 1976)*. Sep 1 2000;25(17):2229-
41 2233

- 1 Stead, L. F., & Lancaster, T. (2012). Combined pharmacotherapy and behavioral
2 interventions for smoking cessation. *Cochrane Database Syst Rev*, 10, CD008286
3
- 4 U.S. Food and Drug Administration. E-Cigarettes, Vapes, and other Electronic Nicotine
5 Delivery Systems (ENDS). Retrieved on January 22, 2024 from
6 [https://www.fda.gov/TobaccoProducts/Labeling/ProductsIngredientsComponents/uc](https://www.fda.gov/TobaccoProducts/Labeling/ProductsIngredientsComponents/ucm456610.htm)
7 [m456610.htm](https://www.fda.gov/TobaccoProducts/Labeling/ProductsIngredientsComponents/ucm456610.htm)
8
- 9 U.S. Preventive Services Task Force (USPSTF). (2021). Tobacco Smoking Cessation in
10 Adults, Including Pregnant Persons: Interventions Retrieved January 22, 2024, from
11 [https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/tobacco-use-](https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/tobacco-use-in-adults-and-pregnant-women-counseling-and-interventions)
12 [in-adults-and-pregnant-women-counseling-and-interventions](https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/tobacco-use-in-adults-and-pregnant-women-counseling-and-interventions)
13
- 14 United States Public Health Service Office of the Surgeon General; National Center for
15 Chronic Disease Prevention and Health Promotion (US) Office on Smoking and
16 Health. Smoking Cessation: A Report of the Surgeon General [Internet]. Washington
17 (DC): US Department of Health and Human Services; 2020. Chapter 6, Interventions
18 for Smoking Cessation and Treatments for Nicotine Dependence. Available from:
19 <https://www.ncbi.nlm.nih.gov/books/NBK555596/>
20
- 21 Whitlock, E. P., Orleans, C. T., Pender, N., & Allan, J. (2002). Evaluating primary care
22 behavioral counseling interventions: An evidence-based approach. *American Journal*
23 *of Preventive Medicine*, 22(4), 267-284